Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03327051 · ClinicalTrials.gov registry record · Phase 4
Gastric Acid Suppression and Probiotic Colonization
A Phase 4 study of Probiotics, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT03327051: Completed Phase 4 study of Probiotics, sponsored by Stanford University.
NCT03327051 is a Phase 4 study of Probiotics that has completed, run by Stanford University. The registered enrollment target is 39 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03327051, a Phase 4 study of Probiotics, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Probiotics are over-the-counter dietary products with microorganisms that are generally consumed for health benefit. However, the durability of these microorganisms is unclear, particularly when they pass through the highly acidic environment of the stomach. We will test the colonization of these microorganisms among individuals who consume probiotics with and without acid suppression therapy.
Primary Outcome
Relative abundance is reported as the percent of combined VSL #3 probiotic bacteria strains in the bacteria sample (S. thermophiles, B. breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp. bulgaricus) following their ingestion in the presence or absence of the gastric acid suppression drug omeprazole. Stool samples were assessed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omeprazole
- DIETARY_SUPPLEMENT VSL #3
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2018-12-30 |
| Phase | Phase 4 |
What the finished NCT03327051 record still lists
NCT03327051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Probiotics appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03327051 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03327051 about?
NCT03327051 is a clinical study titled "Gastric Acid Suppression and Probiotic Colonization". Probiotics are over-the-counter dietary products with microorganisms that are generally consumed for health benefit. However, the durability of these microorganisms is unclear, particularly when they pass through the highly acidic environment of the stomach. We will test the colonization of these mi...
What is the current status of trial NCT03327051?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2018-03-20. Estimated completion is 2018-12-30.
What conditions does trial NCT03327051 study?
This clinical trial studies the following conditions: Probiotics.
What interventions are being tested in trial NCT03327051?
The interventions under investigation include: Placebo (DRUG), Omeprazole (DRUG), VSL #3 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03327051?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03327051 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Probiotics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03327051's enrollment target sits among peer trials
39 1468th of 2000 higher than 526 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI